S.R. No. 62 Summary

• Requests the Department of Health to establish a Beneficial Treatments Advisory Council to review and recommend new medicinal mental health treatments, including psilocybin and MDMA.

• Council must examine federal, state, and local laws regarding medicinal mental health treatments; scientific research on safety and efficacy; and professional requirements for prescribing these treatments.

• Council must develop a long-term strategic plan to ensure safe, accessible, and affordable availability of therapeutic psilocybin and MDMA for adults ages 21 and older.

• Council membership includes the Executive Director of the Office of Wellness and Resilience (chair), Attorney General, Chairperson of the State Council on Mental Health, licensed physicians, and representatives from advocacy organizations and research institutions.

• Council must submit a preliminary report by twenty days before the 2024 Regular Session and a final report with proposed legislation by twenty days before the 2025 Regular Session, then dissolve on July 1, 2025.